Agile says it's on track to hit $25-$30 million net annual revenue after a strong performance in its second quarter

Princeton, nj / accesswire / august 17, 2023 / on august 9, agile therapeutics (nasdaq:agrx) released its second-quarter financial results, showing significant growth in revenue from its innovative weekly birth control patch, twirla® (levonorgestrel and ethinyl estradiol), and a widening gross margin thanks to net revenue growth and decreasing operating expenses. "we set single-quarter record highs in demand, net revenue and factory sales, all while reporting another quarterly decrease in operating expenses," agile chairperson and ceo al altomari said in a statement on the company's second-quarter earnings.
AGRX Ratings Summary
AGRX Quant Ranking